Jasper Therapeutics shares are trading higher after Stifel initiated coverage with a Buy rating and a price target of $86.
Portfolio Pulse from Benzinga Newsdesk
Jasper Therapeutics shares are trading higher after Stifel initiated coverage with a Buy rating and a price target of $86.
June 27, 2024 | 12:56 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Jasper Therapeutics shares are trading higher after Stifel initiated coverage with a Buy rating and a price target of $86.
The initiation of coverage by a reputable firm like Stifel with a Buy rating and a high price target is likely to boost investor confidence and drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100